Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, potentially giving Pfizer’s tafamidis franchise another competitor.